PACIFIC-AMI
Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of the oral FXIa inhibitor BAY 2433334 in patients following ACS
- Stadium
- klaar
- Middel
- FXIa inhibitor BAY 2433334
- Populatie
- ASCVD
- Fase
- II
- First Patient In
- 5 augustus 2020
- Last Patient In
- 15 juli 2021
- Last Patient Last Visit
- 10 februari 2022
Studiedirecteur
dr. R.S. Hermanides
Cardioloog
Contact Kantoor
